Technical Analysis for RGEN - Repligen Corporation

Grade Last Price % Change Price Change
F 171.96 1.36% 2.31
RGEN closed up 1.36 percent on Friday, May 14, 2021, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical RGEN trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 1.36%
Multiple of Ten Bearish Other 1.36%
Wide Bands Range Expansion 1.36%
Lower Bollinger Band Touch Weakness 1.36%
Oversold Stochastic Weakness 1.36%
Older End-of-Day Signals for RGEN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% 2 days ago
60 Minute Opening Range Breakout 2 days ago
Rose Above Previous Day's High 2 days ago
Up 2% 2 days ago
Up 1% 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Repligen Corporation Description

Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed ‘plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences IBD 50 Monoclonal Antibody Consumable Products 3 D Chromatography Imaging Agent Orphan Drug Bioprocessing Cell Culture Chromatography Column Bioprocess Growth Factor Products

Is RGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 228.835
52 Week Low 109.38
Average Volume 374,019
200-Day Moving Average 184.70
50-Day Moving Average 198.66
20-Day Moving Average 199.81
10-Day Moving Average 183.44
Average True Range 8.30
ADX 33.25
+DI 9.51
-DI 40.32
Chandelier Exit (Long, 3 ATRs ) 198.09
Chandelier Exit (Short, 3 ATRs ) 189.20
Upper Bollinger Band 237.13
Lower Bollinger Band 162.50
Percent B (%b) 0.13
BandWidth 37.35
MACD Line -9.21
MACD Signal Line -4.81
MACD Histogram -4.3995
Fundamentals Value
Market Cap 9.05 Billion
Num Shares 52.6 Million
EPS 0.83
Price-to-Earnings (P/E) Ratio 208.44
Price-to-Sales 30.43
Price-to-Book 8.75
PEG Ratio 2.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 181.37
Resistance 3 (R3) 181.25 177.99 179.80
Resistance 2 (R2) 177.99 175.60 178.05 179.27
Resistance 1 (R1) 174.98 174.12 176.49 175.10 178.75
Pivot Point 171.72 171.72 172.48 171.78 171.72
Support 1 (S1) 168.71 169.33 170.22 168.83 165.17
Support 2 (S2) 165.45 167.85 165.51 164.65
Support 3 (S3) 162.44 165.45 164.12
Support 4 (S4) 162.56